연구동향 분석

성인 우울증환자에서 세로토닌 노르에피네프린재흡수억제제와 선택적 세로토닌재흡수억제제 사용의 심뇌혈관질환 부작용 발생에 관한 단기간 관찰연구

박경훈 2020년

논문상세정보
인용/피인용
' 성인 우울증환자에서 세로토닌 노르에피네프린재흡수억제제와 선택적 세로토닌재흡수억제제 사용의 심뇌혈관질환 부작용 발생에 관한 단기간 관찰연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • SNRI
  • antidepressants
  • cardiovascular disease
  • cohort study
  • duloxetine
  • high dimensional propensity score
  • ssri
  • systematic review with meta-analysis
  • 고차원성향점수
  • 둘록세틴
  • 심뇌혈관질환
  • 체계적 문헌고찰
  • 코호트 연구
  • 항우울제
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
4,679 0

0.0%

' 성인 우울증환자에서 세로토닌 노르에피네프린재흡수억제제와 선택적 세로토닌재흡수억제제 사용의 심뇌혈관질환 부작용 발생에 관한 단기간 관찰연구' 의 참고문헌

  • randomized trial of duloxetine versus placebo in the management ofChronic low back pain
    16 ( 9 ) :1041-8 . [2009]
  • randomized multicenter trialComparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain
    6 ( 5 ) :346-56 . [2005]
  • placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder
    119 ( 1-3 ) :5-15 [2005]
  • placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis
    14 ( 8 ) :732-44 . [2014]
  • placebo-controlled study of duloxetine for the treatment ofChildren and adolescents with generalized anxiety disorder
    54 ( 4 ) :283-93 [2015]
  • Yano K. Biological and social correlates of blood pressure among Japanese men in Hawaii
    4 ( 3 ) :406-14 [1982]
  • Wang F. An evaluation of the cardiovascular safety profile of duloxetine : Findings from 42 placebo-controlled studies
    30 ( 5 ) :437-55 . [2007]
  • Treatment with duloxetine in adults and the incidence of cardiovascular events
    32 ( 1 ) :23-30 . [2012]
  • Time-dependent covariates in the Cox proportional-hazards regression model
    20:145-57 [1999]
  • The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients : a Nationwide Population-Based Cohort Study
    35 ( 4 ) : e47 . [2020]
  • Systolic and Diastolic Blood Pressure , Pulse Pressure , and Mean Arterial Pressure as Predictors of Cardiovascular Disease Risk in Men
    36 ( 5 ) :801-7 . [2000]
  • Suissa S. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death : a nested case-control study
    340 : c249 . [2010]
  • Spaeth M. A six-month double-blind , placebo-controlled , randomizedClinical trial of duloxetine for the treatment of fibromyalgia .
    1:91-102 [2008]
  • Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 inCultured rat aortic endothelialCells
    97 ( 6 ) : 1697-702 . [2011]
  • Serotonin and Norepinephrine Reuptake Inhibitors
    145-80 [2019]
  • Schneeweiss S. Regularized Regression Versus the High-Dimensional Propensity Score forConfounding Adjustment in Secondary Database Analyses
    182 ( 7 ) :651-9 . [2015]
  • S. A guide for the utilization of health insurance review and assessment service national patient samples
    36 : e2014008 . [2014]
  • Resting Heart Rate is a Risk Factor forCardiovascular and Noncardiovascular Mortality : TheChicago Heart Association Detection Project In Industry
    149 ( 9 ) :853-62 . [1999]
  • Psychopharmacology andCardiovascular Disease
    71 ( 20 ) :2346-59 . [2018]
  • PRISMA harmsChecklist : improving harms reporting in systematic reviews
    352 : i157 . [2016]
  • Nwulia E. Depression and heart disease in US adults
    34 ( 3 ) :254-61 . [2012]
  • Mehta R. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia : results from a randomized controlled trial
    17 ( 1 ) :27 . [2019]
  • M. L. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation
    42 ( 4 ) :474-80 . [2003]
  • Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease .
    26 ( 10 ) :967-74 . [2005]
  • Longterm fine particulate matter exposure and cardiovascular mortality in the general population : a nationwide cohort study
    75 ( 5 ) :549-58 . [2020]
  • Lesperance F. Reflections on depression as a cardiac risk factor
    67 Suppl 1 : S19-25 . [2005]
  • Kim S. Prescription pattern of antidepressants among the Korean patients with depressionSeoul , Republic of Korea
    [2018]
  • Hypertension and Borderline Isolated Systolic Hypertension Increase Risks of Cardiovascular Disease and Mortality in Male Physicians
    95 ( 5 ) :1132-7 [1997]
  • High-dimensional propensity score adjustment in studies of treatment effects using health care claims data
    20 ( 4 ) :512-22 . [2009]
  • H. Socioeconomic status and depression as combined risk factors for acute myocardial infarction and stroke : A population-based study of 2.7 million Korean adults
    121:14-23 [2019]
  • Food and Drug Administration Regulation of Drugs That Raise Blood Pressure
    20 ( 1 ) :5-8 . [2014]
  • Efficacy and safety of duloxetine in patients withChronic low back pain
    35 ( 13 ) : E578-85 . [2010]
  • Effects of selective serotonin reuptake inhibitors on platelet function : mechanisms , clinical outcomes and implications for use in elderly patients
    28 ( 5 ) :345-67 [2011]
  • Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China
    124 ( 20 ) :3260-8 [2011]
  • Duloxetine increases serotonin and norepinephrine availability in healthy subjects : a double-blind , controlled study
    28 ( 9 ) :1685-93 . [2003]
  • Duloxetine in the treatment of major depressive disorder : a placeboand paroxetine-controlled trial
    21 ( 6 ) :367-78 . [2006]
  • Duloxetine in the treatment of depression : a doubleblind placebo-controlled comparison with paroxetine
    24 ( 4 ) :389-99 . [2004]
  • Duloxetine in the prevention of depressive recurrences : a randomized , double-blind , placebo-controlled trial
    70 ( 5 ) :706-16 . [2009]
  • Duloxetine for treating painful neuropathy , chronic pain or fibromyalgia
    1 : CD007115 . [2014]
  • Duloxetine and cardiovascular adverse events : A systematic review and metaanalysis
    [2020]
  • Diet and lifestyle recommendations revision 2006 : A scientific statement from the American heart association nutrition committee
    114 ( 1 ) :82-96 . [2006]
  • Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
    35 ( 3 ) : 593-604 . [2019]
  • Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo , human serotonin receptor subtypes , and other neuronal receptors
    25 ( 6 ) :871-80 . [2001]
  • Collins R. Agespecific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61 prospective studies
    360 ( 9349 ) :1903-13 [2002]
  • Changes in plasma norepinephrine , blood pressure and heart rate during physical activity in hypertensive man
    1 ( 4 ) : 341-6 . [1979]
  • Cerebrovascular , Cardiovascular , and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors : A Propensity ScoreMatched Population-Based Study
    37 ( 3 ) :332-40 . [2017]
  • Cardiovascular profile of duloxetine , a dual reuptake inhibitor of serotonin and norepinephrine .
    25 ( 2 ) :132-40 . [2005]
  • Blood pressure variability and cardiovascular disease : systematic review and meta-analysis
    354 : i4098 .
  • Blood pressure and incidence of twelve cardiovascular diseases : lifetime risks , healthy life-years lost , and age-specific associations in 125 million people
    383 ( 9932 ) :1899-911 . [2014]
  • Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder : a placebo- and paroxetinecontrolled trial
    14 ( 6 ) :457-70 . [2004]
  • Association of smoking cessation after atrial fibrillation diagnosis on the risk of cardiovascular disease : a cohort study of South Korean men
    20 ( 1 ) :168 [2020]
  • A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms
    27 ( 10 ) :1849-58 [2011]
  • A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder
    22 ( 4 ) :417-25 . [2008]
  • A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder
    24 ( 4 ) :180-9 [2014]
  • A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder
    24 ( 4 ) :170-9 [2014]
  • 7. Agency for Healthcare Research and Quality. Prescribed drugs. Available from: https://meps.ahrq.gov/mepstrends/hc_pmed.
  • 46. Julius S. Transition from high cardiac output to elevated vascular resistance in hypertension. Am Heart J. 1988;116(2, Part 2):600-6.
  • 29. SM Grundy, JI Cleeman, SR Daniels, KA Donato, RH Eckel, BA Franklin et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
  • 21. Health Insurance Review and Assessment Service. Standards guide for calculating disease behavior statistics. 2018. Available from: https://opendata.hira.or.kr/op/opc/selectStcPblc.do?sno=12201&od PblcTpCd=004&searchCnd=&searchWrd=&pageIndex=1.
  • 1. World Health Organization. Cardiovascular diseases (CVDs) 2017. Available from: https://www.who.int/news-room/factsheets/detail/cardiovascular-diseases-(cvds).